Sun Pharma Advanced Falls 5% on Parkinson’s Drug Trial Halt
On April 10, Sun Pharma Advanced Research Company (SPARC) witnessed a 5% decline, hitting the lower circuit, subsequent to the company’s announcement of discontinuing its Phase 2 trial on Vodobatinib for Parkinson’s disease, a significant setback for the Mumbai-based pharmaceutical firm. The PROSEEK study, which spanned across multiple continents including the United States, Europe, and … Read more